# Hansa Biopharma > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/hansabiopharma). ## Overview Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company has pioneered a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, primarily used for desensitizing highly sensitized kidney transplant patients. Hansa's proprietary IgG-cleaving enzyme technology platform supports its drug discovery and development pipeline, targeting transplantation, autoimmune diseases, gene therapy, and new therapies. Headquartered in Lund, Sweden, Hansa operates in Europe and the U.S., aiming to address areas with limited treatment options. ## Products & services • IDEFIRIX for kidney transplant desensitization • Imlifidase enzyme therapy • HNSA-5487 next-generation IgG-cleaving molecule • Gene therapy pre-treatment solutions • Autoimmune disease treatments - **Transplantation** (40%) — Includes therapies for kidney transplant desensitization. - **Autoimmune Diseases** (25%) — Therapies targeting autoimmune conditions. - **Gene Therapy** (20%) — Pre-treatment solutions for gene therapy applications. - **New Therapies** (15%) — Development of novel treatments for rare conditions. - IDEFIRIX for kidney transplant desensitization - Imlifidase enzyme therapy - HNSA-5487 next-generation IgG-cleaving molecule - Gene therapy pre-treatment solutions - Autoimmune disease treatments ## Customers Hansa Biopharma's customer base primarily includes healthcare providers and institutions involved in organ transplantation and treatment of rare immunological conditions. The company's products are critical for highly sensitized kidney transplant patients, offering a unique solution where traditional options are limited. Additionally, Hansa collaborates with gene therapy companies to enhance treatment efficacy for patients with pre-existing antibodies. The focus on rare and underserved conditions attracts specialized healthcare providers seeking innovative solutions for complex medical challenges. - **Transplant Centers** (primary) — Purchase IDEFIRIX for desensitizing kidney transplant patients. - **Autoimmune Disease Clinics** (secondary) — Use therapies for treating complex autoimmune conditions. - **Gene Therapy Companies** (emerging) — Collaborate for pre-treatment solutions to enhance gene therapy. - Healthcare providers specializing in organ transplantation - Institutions treating rare immunological conditions - Gene therapy companies seeking pre-treatment solutions - Specialized healthcare providers for autoimmune diseases ## Geography Hansa Biopharma is headquartered in Lund, Sweden, with significant operations in Europe and the United States. The company focuses on markets where there is a high demand for innovative treatments for rare conditions, particularly in regions with advanced healthcare systems. Hansa's presence in these key markets allows it to collaborate with leading healthcare institutions and gene therapy companies. The geographic focus supports the company's strategic aim to address unmet medical needs in transplantation and autoimmune diseases. - Headquartered in Lund, Sweden - Operations in Europe and the U.S. - Focus on markets with advanced healthcare systems - Collaborations with leading healthcare institutions ## Strategy Hansa Biopharma's strategic priorities include advancing its clinical pipeline across core therapeutic areas such as transplantation, autoimmune diseases, and gene therapy. The company aims to expand the use of its IgG-cleaving enzyme technology to address unmet medical needs. Hansa is also focused on strengthening partnerships with gene therapy companies to enhance treatment efficacy. The strategic direction emphasizes innovation and collaboration to maintain a competitive edge in the biopharmaceutical industry. - **Pipeline Advancement** (medium-term) — To address unmet medical needs in core therapeutic areas. - **Partnership Expansion** (short-term) — To enhance treatment efficacy in gene therapy. - Advance clinical pipeline in transplantation and autoimmune diseases - Expand use of IgG-cleaving enzyme technology - Strengthen partnerships with gene therapy companies - Focus on innovation and collaboration ## Risks Hansa Biopharma faces several business and financial risks, including the inherent uncertainties in drug development and regulatory approval processes. The company's reliance on successful clinical trials and partnerships for revenue generation poses a risk if expected outcomes are not achieved. Additionally, fluctuations in product sales due to the unpredictable nature of organ allocation systems can impact financial performance. Industry-specific risks include competition from other biopharmaceutical companies and potential changes in healthcare regulations. - **Drug Development Uncertainty** [critical] — Clinical trials may not achieve expected outcomes. - **Sales Fluctuations** [high] — Organ allocation systems impact product sales. - Uncertainties in drug development and regulatory approval - Reliance on clinical trials and partnerships for revenue - Fluctuations in product sales due to organ allocation systems - Competition from other biopharmaceutical companies ## Accounting Hansa Biopharma's financial statements are prepared in accordance with IFRS, with specific attention to revenue recognition and the capitalization of development expenses. The timing of revenue recognition, particularly for contract revenue, can impact reported earnings. Capitalized development costs related to IDEFIRIX are amortized over their useful life, affecting long-term financial performance. The company's use of long-term incentive programs also introduces non-cash expenses that influence profit and loss statements. - **Revenue Recognition** — high - **Development Cost Capitalization** — medium - Revenue recognition timing affects reported earnings - Capitalization and amortization of development expenses - Non-cash expenses from long-term incentive programs - Impact of IFRS compliance on financial statements --- *Last updated: 2026-08-11T04:04:53.042344+00:00*